- Molecular NameCiclopirox
- Synonymciclopirox; Ciclopirox Olamin; Ciclopirox-Olamin; ciclopiroxolamine; Ciclopiroxum [INN-Latin]; CPO; HOE 296b; HOE-296b
- Weight207.273
- Drugbank_IDDB01188
- ACS_NO29342-05-0
- Show 2D model
- LogP (experiment)2.33
- LogP (predicted, AB/LogP v2.0)1.63
- pkaN/A
- LogD (pH=7, predicted)0.59
- Solubility (experiment)0.27 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.98
- LogSw (predicted, AB/LogsW2.0)0.54
- Sw (mg/ml) (predicted, ACD/Labs)0.34
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds1
- TPSA40.54
- StatusFDA approved
- AdministrationTopical (applied as a nail lacquer)
- PharmacologyA synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed after oral administration. Mean absorption of ciclopirox after application to nails of all twenty digits and adjacent 5 millimeters of skin once daily for 6 months in patients with dermatophytic onychomycoses was less than 5% of the applied dose. Ciclopirox olamine also penetrates into hair and through the epidermis and hair follicles into sebaceous glands and dermis.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding95.5
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmGlucuronidation is the main metabolic pathway of ciclopirox.
- Half life1.7 hours for 1% topical solution.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)>10 ml/kg
- LD50 (mouse)N/A